Latest Insider Transactions at Quest Diagnostics Inc (DGX)
This section provides a real-time view of insider transactions for Quest Diagnostics Inc (DGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of QUEST DIAGNOSTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of QUEST DIAGNOSTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2024
|
Mark A Gardner SVP of Molecular Gen & Oncol |
SELL
Payment of exercise price or tax liability
|
Direct |
262
-5.18%
|
$33,012
$126.36 P/Share
|
|
Feb 28
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,020
-1.93%
|
$632,520
$126.36 P/Share
|
|
Feb 23
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
3,757
-4.69%
|
$469,625
$125.02 P/Share
|
|
Feb 23
2024
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
9,314
+10.42%
|
$1,164,250
$125.02 P/Share
|
|
Feb 23
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
869
-5.03%
|
$108,625
$125.02 P/Share
|
|
Feb 23
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,388
+12.14%
|
$298,500
$125.02 P/Share
|
|
Feb 23
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,825
-5.91%
|
$353,125
$125.02 P/Share
|
|
Feb 23
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
7,569
+13.68%
|
$946,125
$125.02 P/Share
|
|
Feb 23
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,525
-4.75%
|
$815,625
$125.02 P/Share
|
|
Feb 23
2024
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
13,390
+8.87%
|
$1,673,750
$125.02 P/Share
|
|
Feb 23
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
631
-1.77%
|
$78,875
$125.02 P/Share
|
|
Feb 23
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,689
+4.52%
|
$211,125
$125.02 P/Share
|
|
Feb 23
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-3.86%
|
$77,375
$125.02 P/Share
|
|
Feb 23
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,039
+11.29%
|
$254,875
$125.02 P/Share
|
|
Feb 23
2024
|
Vicky B Gregg Director |
SELL
Open market or private sale
|
Direct |
2,500
-13.28%
|
$315,000
$126.64 P/Share
|
|
Feb 22
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
821
-1.15%
|
$103,446
$126.14 P/Share
|
|
Feb 22
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
661
-1.62%
|
$83,286
$126.14 P/Share
|
|
Feb 21
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
762
-0.61%
|
$95,250
$125.02 P/Share
|
|
Feb 21
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
139
-0.92%
|
$17,375
$125.02 P/Share
|
|
Feb 21
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.26%
|
$11,125
$125.02 P/Share
|
|
Feb 21
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-0.68%
|
$61,625
$125.02 P/Share
|
|
Feb 21
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-0.72%
|
$12,750
$125.02 P/Share
|
|
Feb 21
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
407
-0.99%
|
$50,875
$125.02 P/Share
|
|
Feb 14
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,446
+13.99%
|
-
|
|
Feb 14
2024
|
Mark A Gardner SVP of Molecular Gen & Oncol |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+30.8%
|
-
|
|
Feb 14
2024
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
22,251
+15.12%
|
-
|
|
Feb 14
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
558
+1.61%
|
-
|
|
Feb 14
2024
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
4,304
+5.63%
|
-
|
|
Feb 14
2024
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,348
+28.72%
|
-
|
|
Feb 14
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,641
+15.8%
|
-
|
|
Feb 14
2024
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,478
+19.94%
|
-
|
|
Feb 14
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,935
+6.64%
|
-
|
|
Jan 31
2024
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
88
+0.47%
|
$11,352
$129.33 P/Share
|
|
Jan 31
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
29
+0.25%
|
$3,741
$129.33 P/Share
|
|
Jan 31
2024
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17
+0.1%
|
$2,193
$129.33 P/Share
|
|
Jan 31
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
50
+0.4%
|
$6,450
$129.33 P/Share
|
|
Oct 23
2023
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
18
+0.11%
|
$2,196
$122.86 P/Share
|
|
Oct 23
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
52
+0.41%
|
$6,344
$122.84 P/Share
|
|
Oct 23
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
30
+0.26%
|
$3,660
$122.86 P/Share
|
|
Oct 23
2023
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
92
+0.49%
|
$11,224
$122.86 P/Share
|
|
Sep 25
2023
|
Mark A Gardner SVP of Molecular Gen & Oncol |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-3.97%
|
$14,616
$126.22 P/Share
|
|
Aug 15
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
74
-0.65%
|
$9,990
$135.23 P/Share
|
|
Jul 25
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
44
+0.35%
|
$6,336
$144.59 P/Share
|
|
Jul 25
2023
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
78
+0.42%
|
$11,232
$144.59 P/Share
|
|
Jul 25
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
25
+0.22%
|
$3,600
$144.59 P/Share
|
|
Jul 14
2023
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,909
-19.18%
|
$547,260
$140.18 P/Share
|
|
May 17
2023
|
Luis Diaz Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,369
+50.0%
|
-
|
|
May 17
2023
|
Tracey Doi Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,369
+27.43%
|
-
|
|
May 17
2023
|
Wright Lassiter Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,369
+18.35%
|
-
|
|
May 17
2023
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,369
+5.05%
|
-
|